Mitochondrial Energy Optimizer

Description

Helps to counteract age-related cellular energy changes, promotes cellular regeneration, protects against free radical damage.

Mitochondrial Energy Optimizer with BioPQQ™ not only protects delicate cellular structures and enables cells to perform life-sustaining metabolic processes, it also helps generate new mitochondria! This formula is designed to counteract age-related structural and functional changes and promote biogenesis with these unique ingredients:

• PQQ (Pyrroloquinoline quinone) — this next generation cellular rejuvenator triggers growth of new mitochondria in aging cells10 … and activates genes involved in protecting delicate structures within the mitochondria.11-14
• Carnosine — As humans age, their proteins become irreversibly damaged by lethal glycation reactions. Glycation is the cross-linking of proteins and sugar to form non-functioning structures in the body, which can lead to alterations of normal cell function. Carnosine is not only the premier anti-glycating agent, but it also protects neurons against reactive and cytotoxic protein carbonyl species associated with normal aging.15-19
• Luteolin — Unremitting systemic inflammation is involved with virtually every undesirable consequence of aging. Culprits behind chronic inflammatory reactions are pro-inflammatory cytokines, such as interleukin-1 and tumor necrosis factor alpha. Luteolin is a super-potent plant extract that has been shown to suppress these dangerous inflammatory cytokines.20-26
• Benfotiamine — Benfotiamine blocks multiple destructive biochemical pathways, including AGEs’ formation pathway, which is induced by higher than desirable blood glucose levels. Human mortality studies indicate that ideal fasting glucose levels are between 74–85 mg/dL. Yet many aging people have fasting glucose above 90 mg/dL, which is less than optimal.27-29 Benfotiamine can activate glucose metabolism and promote already healthy blood glucose levels. In addition, benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage.30
• Pyridoxal 5′-Phosphate — Aging results in the formation of toxic advanced glycation end products throughout the body. Pyridoxal 5′-phosphate is the active form of vitamin B6 that has been shown to protect against both lipid and protein glycation reactions.31-33
• R-Lipoic Acid — Destructive free radical activity in the mitochondria plays a major role in the loss of cellular vitality. The microencapsulated Bio-Enhanced® R-lipoic acid facilitates youthful mitochondrial energy output while guarding against free radicals. Two forms of lipoic acid are sold on the supplement market, but R-lipoic acid is far more potent.34-39
• Acetyl-L-Carnitine Arginate — The amino acid L-carnitine is required to transport fats into the mitochondria to be burned for cellular energy. ArginoCarn® Acetyl-L-carnitine arginate is a patented form of carnitine that has been shown in cell cultures to stimulate the growth of neurites.40-42

Product # N354 – Mitochondrial Energy Optimizer (120 caps) $70.50
Wellness Club Members save 10% – Member Price only $63.45
Not a Wellness Club Member? Join now and start saving right away!

Enter Quantity Desired and Click “Add To Cart” Button

Supplement Facts

Serving Size 4 capsules – Servings Per Container 30 – Amount Per Serving

Vitamin B6 (as pyridoxal 5’-phosphate)

100 mg

Calcium (as calcium carbonate)

175 mg

Sodium

25 mg

Carnosine

1000 mg

ArginoCarn® Acetyl-L-carnitine arginate dihydrochloride

675 mg

Benfotiamine

150 mg

R-Lipoic Acid (as microencapsulated Bio-Enhanced® stabilized Na-RALA sodium R-lipoate)

150 mg

BioPQQ™ Pyrroloquinoline quinone disodium salt

10 mg

Luteolin (high purity luteolin as Pureolin™)

8 mg

Other ingredients: gelatin, vegetable stearate, silica.

Contains soybeans.

Bio-Enhanced® is a registered trademark of Geronova Research, Inc.
Pureolin™ is a trademark of Pharma Science Nutrients, Inc., and is used here under license. All rights reserved worldwide.
BioPQQ™ is a trademark of MGC (Japan).
ArginoCarn® is a registered trademark of Sigma-tau HealthSciences, Inc. and is protected by US patents 6,365,622, US 6,703,042 and EP1202956.

Dosage and Use

Take two capsules twice daily, preferably early in the day or all at once upon wakening, or as recommended by a healthcare practitioner.

This product can be taken with or without food.

To ensure product consistency, store tightly closed in a cool, dry place.

References: Mitochondrial Support

1. Ann N Y Acad Sci. 2004 Jun;1019:406-11.
2. Postepy Biochem. 2008;54(2):129-41.
3. Ann N Y Acad Sci. 2002 Apr;959:491-507.
4. Chang Gung Med J. 2009 Mar-Apr;32(2):113-32.
5. Proc Natl Acad Sci USA. 1997 94:3064-9.
6. Ann NY Acad. Sci. 1998; 854:118-27.
7. Biochim Biophys Acta. 2000 Jun 26;1486(1):1-17.
8. Acta Physiol Scand. 2003 Aug;178(4):385-90.
9. Int J Sports Med. 1998 May;19(4):231-44.
10. J Biol Chem. 2010. Jan 1;285:142-152.
11. Alt Med Rev. 2009; 14(3):268-77.
12. Entrez Gene: PARGC1A peroxisome proliferator-activated receptor gamma, coactivator 1 alpha [ Homo sapiens ] GeneID: 10891.
13. Entrez Gene: CREBBP CREB binding protein [ Homo sapiens ] GeneID: 1387.
14. Hum Mol Genet. 2008 Nov 1;17(21):3357-67.
15. Hormones (Athens). 2008 Apr-Jun;7(2):123-32.
16. Protein Pept Lett. 2008;15(4):385-91.
17. J Alzheimers Dis. 2007 May;11(2):229-40.
18. Ann N Y Acad Sci. 2006 May;1067:369-74.
19. Sci Aging Knowledge Environ. 2005 May 4;2005(18):pe12.
20. Life Sci. 2007 Nov 30;81(23-24):1602-14.
21. J Nutr. 2006 Jun;136(6):1517-21.
22. J Neuroinflammation. 2008 Sep 25;5:41.
23. Immunology. 2005 Jul;115(3):375-87.
24. Am J Respir Crit Care Med. 2002 Mar 15;165(6):818-23.
25. Eur J Pharmacol. 2006 Jul 10;541(1-2):95-105.
26. Neurosci Lett. 2008 Dec 26;448(2):175-9.
27. Nat Med. 2003 Mar;9(3):294-9.
28. Acta Diabetol. 2001;38(3):135-8.
29. Diabetes. 2006 Aug;55(8):2231-7.
30. Diabetes Metab Res Rev. 2008 Jul-Aug;24(5):371-7
31. J Lipid Res. 2006 May; 47(5): 964-74
32. J Am Soc Nephrol. 2005 Jan;16(1):144-50.
33. Life Sci. 1988;43(21):1725-31.
34. Biochem Biophys Res Commun. 1996 Apr 16;221(2):422-9.
35. FASEB J. 1999 Feb;13(2):411-8.
36. Antioxid Redox Signal. 2000 Fall;2(3):473-83.
37. Biochem Mol Biol Int. 1995 Oct;37(2):361-70.
38. Arch Biochem Biophys. 2004 Mar 1;423(1):126-35.
39. Redox Rep. 2005;10(1):52-60.
40. Altern Med Rev. 2005 Dec;10(4):268-93.
41. Neurosci Lett. 1994 Jan 3;165(1-2):33-6.
42. Neurochem Res. 1995 Jan;20(1):1-9.
43. Biochimie. 1999 Dec;81(12):1131-2.
44. Lancet. 1989 Mar 25;1(8639):642-5.
45. Curr Opin Clin Nutr Metab Care. 2010 Jul 7.
46. Age (Dordr). 2010 Mar 20.
47. Ageing Res Rev. 2010 Jun 25.
48. Cell Mol Life Sci. 2010 Jun 25.
49. Zhonghua Yi Xue Za Zhi (Taipei). 2001 May;64(5):259-70.
50. Cardiovasc Drugs Ther. 2004 Nov;18(6):421-31.
51. J Cardiovasc Pharmacol Ther. 2006 Jun;11(2):119-28.
52. Biochem Biophys Res Commun. 2007 Nov 16;363(2):257-62.
53. FOOD Style. 2009;21:13(7)50-3. [Tokyo].
54. Biofactors. 1999;9(2-4):371-8.
55. Lipids. 1989 Jul;24(7):579-84.
56. Mol Aspects Med. 1994;15 Suppl:s165-s175.
57. Mol Biotechnol. 2007 Sep;37(1):31-7.
58. Systemic CoQ level in animals: Part II. Unpublished study. Natreon, Inc.; 2007.
59. Pharmacologyonline. 2009;1:817-25.
60. Pharmacologyonline. 2009;2:690-8.
61. Electronic Journal of Biotechnology. 2008 Jul 15;11(3).
62. Ghosal S. Shilajit in Perspective. Alpha Science International Limited; 2006.
63. Kaneka Corp. Unpublished study. 2007.
64. Sci Total Environ. 1987 Apr;62:347-54.
65. Environ Sci Technol. 2002 Jul 15;36(14):3170-5.
66. Environ Sci Technol. 2002 May 1;36(9):1939-46.
67. Environ Sci Technol. 2009 Feb 1;43(3):878-83.
68. Regul Toxicol Pharmacol. 2007 Feb;47(1):19-28.
69. KANEKA CORP. Anti-fatigue effect in rats. Unpublished data, Kaneka Corp.
70. Exp Gerontol. 2006 Feb;41(2):130-40.
71. Ubiquinol has a higher bioavailability compared to ubiquinone. Unpublished data, Kaneka Corp.
72. Plasma levels of COQ10 for ubiquinol increased dose dependently. Unpublished data, Kaneka Corp.
73. LEF internal unpublished study 2006
74. Skin Pharmacol. 1994;7(5):278-84.
75. Circulation. 2008 Jan 22;117(3):421-8. Epub 2007 Dec 24.
76. Wien Klin Wochenschr. 2006 Mar;118(3-4):100-7.
77. Eur J Pharm Sci. 1999 Apr;8(1):57-65.
78. Free Radic Res. 2004 Oct;38(10):1083-92.
79. Biochem Mol Biol Int. 1998 Oct;46(3):585-95.
80. Am J Physiol. 1997 Jul;273(1 Pt 1):E185-E191.
81. Biochem Pharmacol. 1996 Feb 9;51(3):233-8.
82. J Mol Cell Cardiol. 1995 Sep;27(9):1895-903.
83. Z Naturforsch [C]. 1994 Sep-Oct;49(9-10):691-2.
84. Carlson DA, et al. Lipoic Acid: Energy Production, Antioxidant Activity and Health Effects. Taylor & Francis Publishers; 2008:235-70.
85. Med Rev. 2007 Dec;12(4):343-51.
86. Int J Sport Nutr Exerc Metab.2008 Feb;18(1):19-36.
87. J Physiol. 2007 Jun 1;581(Pt 2):431-44. Epub 2007 Mar 1.
88. Exp Physiol. 2008 Oct;93(10):1139-46.
89. Mol Aspects Med. 2004 Oct-Dec;25(5-6):533-49.
90. Clin Exp Pharmacol Physiol. 2006 Aug;33(8):725-33.
91. Neuropharmacology. 2008 Aug;55(2):223-9.
92. Neuropharmacology. 2006 Jun;50(8):917-23.
93. J Neurosci Res. 1991 Nov;30(3):555-9.
94. Neurochem Res. 1993 May;18(5):573-8.
95. Mol Cell Biochem.2003 Dec;254(1-2):227-34
96. J Int Soc Sports Nutr. 2007 Dec 3;4:22.
97. Int J Sport Nutr Exerc Metab. 2008 Feb;18(1):19-36.
98. Res Sports Med. 2009 Jan-Mar;17(1):1-16.
99. J Int Soc Sports Nutr. 2009 Apr 2;6:9.
100. Int J Vitam Nutr Res. 2009 May;79(3):131-41.
101. J Int Soc Sports Nutr. 2010 May 6;7:16.
102. Int J Vitam Nutr Res. 2010 Jan;80(1):12-23.
103. J Int Soc Sports Nutr. 2010 Oct 28;7:35.
104. Neurochem Res. 2008 Nov 1. [Epub ahead of print]
105. Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Jun;28(3):113-20.
106. Mol Aspects Med. 2004 Oct-Dec;25(5-6):551-67.
107. Ann N Y Acad Sci. 2002 Apr;959:491-507.
108. J Appl Physiol. 1999 Apr;86(4):1191-6.
109. Chem Biol Interact. 2006 Nov 7;163(3):192-8.
110. Nutrition. 2007 Jan;23(1):76-80.
111. Am J Physiol Cell Physiol. 2007 Oct;293(4):C1395-403.
112. Pharmacol Ther. 2007 Jan;113(1):154-64.
113. Toxicol Lett. 2005 Dec 30;160(1):1-7.
114. Chem Biol Interact. 2004 Apr 15;147(3):259-71.
115. Chem Biol Interact. 2001 Nov 28;138(2):189-98.
116. Neurochem Res. 2007 Sep;32(9):1552-8
117. Drug Metab Rev. 1998 May;30(2):245-75.
118. Free Radic Biol Med. 1997;22(1-2):359-78.
119. Free Radic Biol Med. 2001 Jul 1;31(1):53-61.
120. Z Naturforsch [C]. 1998 Mar-Apr;53(3-4):250-3.
121. Nutrition. 2001 Oct;17(10):888-95.
122. Gen Pharmacol. 1997 Sep;29(3):315-31.
123. Biochim Biophys Acta 1988 Dec 16;963(3):558-61
124. Biochem Biophys Res Commun 1990 Jun 29;169(3):851-7.